Navigation Links
Nasulin Interim Results to Be Presented at American Diabetes,Association Scientific Sessions

EXETER, N.H.--(BUSINESS WIRE)--Apr 10, 2007 - Bentley Pharmaceuticals, Inc. (NYSE: BNT), a specialty pharmaceutical company, today announced that its abstract entitled "Interim Results of a Randomized, Single-Dose, 4-Way Crossover, Pharmacokinetic Study of Intranasal Insulin Spray (Nasulin(TM)), Injectable Regular Insulin (Humulin R(R)), Injectable Fast-Acting Insulin (Humalog(R)), and Saline Nasal Spray in Patients with Type I Diabetes Mellitus," has been selected for oral presentation at the American Diabetes Association 67th Scientific Sessions in Chicago. Dr. Sherwyn L. Schwartz, M.D., of dgd Research, Inc., will make the presentation as part of the first session on Friday, June 22, 2007.

Another Bentley sponsored study has also been accepted for a poster presentation in the category Clinical Therapeutics/New Technology - Insulin Delivery Systems. The poster abstract, "Intranasulin Insulin Spray (Nasulin(TM)) in Healthy Subjects: Choice of Nostril," will be displayed Saturday through Monday, June 23-25, 2007, in the General Poster Session in the Exhibit Hall.

Founded in 1979 by Dr. Schwartz, the Diabetes & Glandular Disease Clinic is the largest private endocrine clinic in the United States with over 70,000 active patients, eight board certified endocrinologists, seven NPs/PAs and an ADA recognized diabetes education program. The research arm, dgd Research Associates, Inc., has a staff of over 250 employees and has conducted over 1,500 Phase I through III clinical trials, primarily in targeted endocrine populations. Currently work is underway on construction of a new 80,000sq. ft. Phase I unit. For more information visit www.dgdclinic.com and www.dgdresearch.com.

Bentley Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on advanced drug delivery technologies and generic pharmaceutical products. Bentley's proprietary drug delivery technologies enhance the absorption of pha rmaceutical compounds across various membranes. Bentley manufactures and markets a growing portfolio of generic and branded generic pharmaceuticals in Europe for the treatment of cardiovascular, gastrointestinal, infectious and central nervous system diseases through its subsidiaries -- Laboratorios Belmac, Laboratorios Davur, Laboratorios Rimafar and Bentley Pharmaceuticals Ireland. Bentley also manufactures and markets active pharmaceutical ingredients through its subsidiary, Bentley API.

Additional information regarding Bentley Pharmaceuticals may be obtained through Bentley's web site at www.bentleypharm.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This press release contains forward looking statements, including without limitation, statements regarding plans for the announcement of interim results of a clinical trial of Bentley's intranasal insulin product candidate. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from future results expressed or implied by such statements. Factors that may cause such differences include, but are not limited to risks associated with the efficacy and safety of Bentley's intranasal insulin product candidate and its drug delivery technology, risks associated with international clinical trials, and other risks detailed under Item 1A "Risk Factors" in Bentley's most recent Annual Report on Form 10-K and its subsequent periodic reports filed with the Securities and Exchange Commission. Bentley cautions investors not to place undue reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this document, and Bentley undertakes no obligation to update or revise the statements, except as may be required by law.

Contact

Bentley Pharmaceuticals, Inc.
Jean DeRoche, 603-658-6136
jderoche@bentleypharm.com
or
Sharon Merrill Associates
James R. Buckley, 617-542-5300
Executive Vice President
bnt@investorrelations.com


'"/>




Related medicine technology :

1. Bentley Reports Positive Results with Nasulin Intranasal Insulin Spray at the American Diabetes Association Meeting
2. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
3. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
4. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
5. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
6. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
7. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
8. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
9. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
10. Avalon Pharmaceuticals Announces Positive Interim Results For AVN944 Phase I Trial
11. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... , April 19, 2017 ... an immune response in pets such as canine, ... are of various types such as Attenuated Live ... Vaccines, DNA Vaccines and Recombinant Vaccines. Attenuated live ... virus or bacteria, which have been weakend under ...
(Date:4/18/2017)... DUBLIN, Ohio , April 18, 2017  Cardinal ... its Non-GAAP 1 fiscal 2017 earnings per share ... 2018 and 2019.  This is in conjunction with this ... Care, Deep Vein Thrombosis and Nutritional Insufficiency businesses. ... EPS from continuing operations will be at the bottom ...
(Date:4/18/2017)... DIEGO , April 18, 2017  Astute Medical, ... a case series to be presented at the 2017 ... which begins today and continues through April 22. Physicians ... IGFBP-7 , used to assess risk for acute kidney ... decompensated heart failure (ADHF). Elevated levels ...
Breaking Medicine Technology:
(Date:4/26/2017)... ... April 26, 2017 , ... Elisabete Miranda, ... been honored by Enterprising Women magazine as one of its 2017 Enterprising Women ... business owners. Winners have demonstrated that they have fast-growth businesses, mentor or actively ...
(Date:4/26/2017)... ... April 26, 2017 , ... Miami native and local periodontist ... “I could have never imagined back in 1991 that this journey would have taken ... Over the last 25 years, Dr. Gallardo has pioneered implant dentistry innovation, evolving into ...
(Date:4/26/2017)... ... April 26, 2017 , ... New ... profitability of ready-to-drink, high-protein beverages by helping beverage manufacturers more effectively manage protein ... providing direct cost savings as well as more stable pricing over time. Now ...
(Date:4/25/2017)... ... April 25, 2017 , ... Bellus Medical, a leader ... in a new class of photodynamic cosmetics (PDC). , Allumera® is the first ... outward signs of aging, and minimize the appearance of pores – all with ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... Newport Beach, California, committed to raising awareness for Duchenne muscular dystrophy, and ... its randomized CAP-1002 (cardiosphere-derived cells) Phase I/II HOPE clinical trial in Duchenne ...
Breaking Medicine News(10 mins):